UC awarded 12th patent for CRISPR-Cas9 gene-editing technology
Lianne Frick/File
The UC system and partners University of Vienna and Emmanuelle Charpentier were awarded a 12th patent for the CRISPR-Cas9 gene-editing technology.
Read More…
UC obtains 8th patent for CRISPR gene-editing methods
The UC’s family of eight patents covers CRISPR methods for editing genes in any environment, whether the cells are in a plant, an animal or a human. This newest patent focuses specifically on the use of CRISPR gene editing within cells.
Read More…
UC receives 5th patent for CRISPR-Cas9 gene-editing system
The U.S. Patent and Trademark Office granted the University of California a new patent for the revolutionary CRISPR-Cas9 system of gene-editing technology on Tuesday. The patent, No. 10,301,651, covers methods of modulating DNA transcription.
Read More…
UC Berkeley receives its 4th CRISPR patent, expects 3 more after
On April 23, the U.S. Patent and Trademark Office issued UC Berkeley its fourth patent for CRISPR Cas-9, a revolutionary gene-editing technology.
Read More…
UC Berkeley announces patenting of gene-editing technology CRISPR
UC Berkeley announced Tuesday that the U.S. Patent and Trademark Office has granted a patent to CRISPR, a gene-editing technology.
Read More…
UC Berkeley professor Jennifer Doudna awarded Medal of Honor from American Cancer Society
Campus molecular biology and biochemistry professor Jennifer Doudna was awarded the American Cancer Society’s Medal of Honor on Oct. 18 for her role in developing CRISPR-Cas9, a revolutionary gene-editing technology.
Read More…
Norwegian king awards campus professor Jennifer Doudna 2018 Kavli Prize
Campus molecular biology and biochemistry professor Jennifer Doudna was awarded the 2018 Kavli Prize in nanoscience for her role in discovering CRISPR, a revolutionary gene-editing technology, in a gala hosted by Norwegian King Harald V on Tuesday.
Read More…
Both parties in CRISPR-Cas9 technology lawsuit can maintain patents, board rules
The U.S. Patent Trial and Appeal Board ruled there was no interference between the patents requested by Broad Institute and the University of California regarding CRISPR technology, prompting the UC system to consider further legal steps to secure patent rights over the use of CRISPR-Cas9 in all types of cells and organisms.
Read More…
